# A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07227025/  
OnCo record `nct07227025` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Amivantamab and Olomorasib in non-small-cell lung cancer, run by Janssen Research & Development, LLC, now recruiting.

## Summary

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07227025 by Janssen Research & Development, LLC, with 60 participants planned, started 2026-03-03 and due to reach its primary completion in 2028-11-30. Interventions recorded: Amivantamab and Olomorasib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07227025
- Phase: 1/2
- Setting: A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07227025: https://clinicaltrials.gov/study/NCT07227025

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Amivantamab](https://onco.cc/drugs/amivantamab/), [Olomorasib](https://onco.cc/drugs/olomorasib/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct07227025.json